Table of Contents
Pathology Research International
Volume 2011, Article ID 219309, 11 pages
http://dx.doi.org/10.4061/2011/219309
Review Article

Impact of KRAS Mutations on Management of Colorectal Carcinoma

Department of Medicine, Section of Hematology/Oncology, Albert Einstein College of Medicine, Beth Israel Medical Center, Phillips Ambulatory Care Center, 10 Union Square East, Suite 4C, NY 10003, USA

Received 28 September 2010; Revised 2 January 2011; Accepted 10 January 2011

Academic Editor: Wade Samowitz

Copyright © 2011 Kevin M. Sullivan and Peter S. Kozuch. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. H. Heldin, “Dimerization of cell surface receptors in signal transduction,” Cell, vol. 80, no. 2, pp. 213–223, 1995. View at Google Scholar · View at Scopus
  2. G. Carpenter, “Receptors for epidermal growth factor and other polypeptide mitogens,” Annual Review of Biochemistry, vol. 56, pp. 881–914, 1987. View at Google Scholar · View at Scopus
  3. G. Carpenter and S. Cohen, “Epidermal growth factor,” The Journal of Biological Chemistry, vol. 265, no. 14, pp. 7709–7712, 1990. View at Google Scholar · View at Scopus
  4. F. Loupakis, L. Pollina, I. Stasi et al., “PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 16, pp. 2622–2629, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. A. Citri and Y. Yarden, “EGF-ERBB signalling: towards the systems level,” Nature Reviews Molecular Cell Biology, vol. 7, no. 7, pp. 505–516, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. N. E. Hynes and H. A. Lane, “ERBB receptors and cancer: the complexity of targeted inhibitors,” Nature Reviews Cancer, vol. 5, no. 5, pp. 341–354, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. Downward, Y. Yarden, E. Mayes et al., “Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences,” Nature, vol. 307, no. 5951, pp. 521–527, 1984. View at Google Scholar · View at Scopus
  8. F. X. Real, W. J. Rettig, and P. G. Chesa, “Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation,” Cancer Research, vol. 46, no. 9, pp. 4726–4731, 1986. View at Google Scholar · View at Scopus
  9. NCCN Clinical Practice Guidelines in Oncology. Colon Cancer, vol. 3, NCCN, Gaithersburg, Md, USA, 2010.
  10. C. M. Croce, “Oncogenes and cancer,” The New England Journal of Medicine, vol. 358, no. 5, pp. 502–511, 2008. View at Publisher · View at Google Scholar · View at PubMed
  11. N. Normanno, C. Bianco, A. De Luca, M. R. Maiello, and D. S. Salomon, “Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment,” Endocrine-Related Cancer, vol. 10, no. 1, pp. 1–21, 2003. View at Publisher · View at Google Scholar
  12. L. B. Saltz, N. J. Meropol, P. J. Loehrer, M. N. Needle, J. Kopit, and R. J. Mayer, “Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor,” Journal of Clinical Oncology, vol. 22, no. 7, pp. 1201–1208, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. D. Cunningham, Y. Humblet, S. Siena et al., “Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer,” The New England Journal of Medicine, vol. 351, no. 4, pp. 337–345, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. H. J. Lenz, E. Van Cutsem, S. Khambata-Ford et al., “Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines,” Journal of Clinical Oncology, vol. 24, no. 30, pp. 4914–4921, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. G. Folprecht, M. P. Lutz, P. Schöffski et al., “Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma,” Annals of Oncology, vol. 17, no. 3, pp. 450–456, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. D. J. Jonker, C. J. O'Callaghan, C. S. Karapetis et al., “Cetuximab for the treatment of colorectal cancer,” The New England Journal of Medicine, vol. 357, no. 20, pp. 2040–2048, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. J. Tabernero, E. Van Cutsem, E. Díaz-Rubio et al., “Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 25, no. 33, pp. 5225–5232, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. A. F. Sobrero, J. Maurel, L. Fehrenbacher et al., “EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 14, pp. 2311–2319, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. E. Van Cutsem, M. Nowacki, I. Lang et al., “Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial,” Journal of Clinical Oncology, vol. 25, no. 18, supplement, p. 164s, 2007. View at Google Scholar
  20. E. Van Cutsem, M. Peeters, S. Siena et al., “Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 25, no. 13, pp. 1658–1664, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. L. B. Saltz, H. J. Lenz, H. L. Kindler et al., “Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study,” Journal of Clinical Oncology, vol. 25, no. 29, pp. 4557–4561, 2007. View at Publisher · View at Google Scholar · View at PubMed
  22. N. H. Segal, D. Reidy-Lagunes, M. Capanu et al., “Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (The BOND 2.5 Study),” Journal of Clinical Oncology, vol. 27, no. 15, supplement, 2009, ASCO Annual Meeting, abstract no. 4087. View at Google Scholar
  23. M. Malumbres and M. Barbacid, “RAS oncogenes: the first 30 years,” Nature Reviews Cancer, vol. 3, no. 6, pp. 459–465, 2003. View at Publisher · View at Google Scholar · View at PubMed
  24. R. G. Amado, M. Wolf, M. Peeters et al., “Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1626–1634, 2008. View at Publisher · View at Google Scholar · View at PubMed
  25. C. J. Allegra, J. M. Jessup, M. R. Somerfield et al., “American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 2091–2096, 2009. View at Publisher · View at Google Scholar · View at PubMed
  26. W. De Roock, B. Claes, D. Bernasconi et al., “Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis,” The Lancet Oncology, vol. 11, no. 8, pp. 753–762, 2010. View at Publisher · View at Google Scholar
  27. J. Baselga and N. Rosen, “Determinants of RASistance to anti-epidermal growth factor receptor agents,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1582–1584, 2008. View at Publisher · View at Google Scholar · View at PubMed
  28. S. Khambata-Ford, C. R. Garrett, N. J. Meropol et al., “Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab,” Journal of Clinical Oncology, vol. 25, no. 22, pp. 3230–3237, 2007. View at Publisher · View at Google Scholar · View at PubMed
  29. W. De Roock, H. Piessevaux, J. De Schutter et al., “KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab,” Annals of Oncology, vol. 19, no. 3, pp. 508–515, 2008. View at Publisher · View at Google Scholar · View at PubMed
  30. C. J. Punt, J. Tol, C. J. Rodenburg et al., “Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group,” Journal of Clinical Oncology, vol. 26, supplement, 2008, abstract LBA 4011. View at Google Scholar
  31. C. Bokemeyer, I. Bondarenko, A. Makhson et al., “Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 5, pp. 663–671, 2009. View at Publisher · View at Google Scholar · View at PubMed
  32. S. Tejpar, M. Peeters, Y. Humblet et al., “Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer, treated with irinotecan and escalating doses of cetuximab: the EVEREST experience (preliminary data),” Journal of Clinical Oncology, vol. 26, supplement, 2008, abstract no. 4001. View at Google Scholar
  33. E. Van Cutsem, C. H. Köhne, E. Hitre et al., “Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 360, no. 14, pp. 1408–1417, 2009. View at Publisher · View at Google Scholar · View at PubMed
  34. A. Lièvre, J. B. Bachet, V. Boige et al., “KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab,” Journal of Clinical Oncology, vol. 26, no. 3, pp. 374–379, 2008. View at Publisher · View at Google Scholar · View at PubMed
  35. C. S. Karapetis, S. Khambata-Ford, D. J. Jonker et al., “K-ras mutations and benefit from cetuximab in advanced colorectal cancer,” The New England Journal of Medicine, vol. 359, no. 17, pp. 1757–1765, 2008. View at Publisher · View at Google Scholar · View at PubMed
  36. D. Santini, F. Loupakis, B. Vincenzi et al., “High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice,” Oncologist, vol. 13, no. 12, pp. 1270–1275, 2008. View at Publisher · View at Google Scholar · View at PubMed
  37. S. Artale, A. Sartore-Bianchi, S. M. Veronese et al., “Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 25, pp. 4217–4219, 2008. View at Publisher · View at Google Scholar · View at PubMed
  38. M. C. Etienne-Grimaldi, J. L. Formento, M. Francoual et al., “K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy,” Clinical Cancer Research, vol. 14, no. 15, pp. 4830–4835, 2008. View at Publisher · View at Google Scholar · View at PubMed
  39. G. Folprecht, T. Gruenberger, W. O. Bechstein et al., “Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial,” The Lancet Oncology, vol. 11, no. 1, pp. 38–47, 2010. View at Publisher · View at Google Scholar
  40. S. E. Baldus, K. L. Schaefer, R. Engers, D. Hartleb, N. H. Stoecklein, and H. E. Gabbert, “Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases,” Clinical Cancer Research, vol. 16, no. 3, pp. 790–799, 2010. View at Publisher · View at Google Scholar · View at PubMed
  41. A. Mancuso, R. Sollami, F. Recine et al., “Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy,” Journal of Clinical Oncology, vol. 28, no. 36, pp. e756–e758, 2010. View at Google Scholar
  42. E. Van Cutsem, I. Lang, G. Folprecht et al., “Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL trial,” in Proceedings of the Gastrointestinal Cancers Symposium, Orlando, Fla, USA, January 2010, abstract no. 281.
  43. C. Bokemeyer , I. Bondarenko, J. T. Hartmann et al., “Biomarkers predictive for outcome in patients with metastatic colorectal cancer treated with first-line FOLFOX4 plus or minus cetuximab: updated data from the OPUS study,” in Proceedings of the ASCO Gastrointestinal Cancers Symposium, Orlando, Fla, USA, January 2010, abstract no. 428.
  44. S. Siena, J. Cassidy, J. Tabernero et al., “Randomized phase III study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as first-line treatment for metastatic colorectal cancer: PRIME trial,” in Proceedings of the Gastrointestinal Cancers Symposium, Orlando, Fla, USA, January 2010, abstract no. 283.
  45. C. Kohne, K. Mineur, R. Greil et al., “Primary analysis of a phase II study (20060314) combining first-line panitumumab with FOLFIRI in the treatment of patients with metastatic colorectal cancer,” in Proceedings of the Gastrointestinal Cancers Symposium, Orlando, Fla, USA, January 2010, abstract no. 414.
  46. J. Hecht, E. Mitchell, J. Baranda et al., “Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1–9%) or negative (<1%) levels of epidermal growth receptor (EGFr),” Journal of Clinical Oncology, vol. 24, supplement, 2006, abstract no. 3506. View at Google Scholar
  47. F. Di Fiore, F. Blanchard, F. Charbonnier et al., “Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy,” British Journal of Cancer, vol. 96, no. 8, pp. 1166–1169, 2007. View at Publisher · View at Google Scholar · View at PubMed
  48. S. Benvenuti, A. Sartore-Bianchi, F. Di Nicolantonio et al., “Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies,” Cancer Research, vol. 67, no. 6, pp. 2643–2648, 2007. View at Publisher · View at Google Scholar · View at PubMed
  49. J. Tol, M. Koopman , A. Cats et al., “Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer,” The New England Journal of Medicine, vol. 360, pp. 563–572, 2009. View at Google Scholar
  50. J. R. Hecht, E. Mitchell, T. Chidiac et al., “A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 5, pp. 672–680, 2009. View at Publisher · View at Google Scholar · View at PubMed
  51. H. Linardou, I. J. Dahabreh, D. Kanaloupiti et al., “Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer,” The Lancet Oncology, vol. 9, no. 10, pp. 962–972, 2008. View at Publisher · View at Google Scholar · View at PubMed
  52. J. L. Bos, E. R. Fearon, S. R. Hamilton et al., “Prevalence of ras gene mutations in human colorectal cancers,” Nature, vol. 327, no. 6120, pp. 293–297, 1987. View at Google Scholar
  53. B. Vogelstein, E. R. Fearon, S. R. Hamilton et al., “Genetic alterations during colorectal-tumor development,” The New England Journal of Medicine, vol. 319, no. 9, pp. 525–532, 1988. View at Google Scholar
  54. D. Lambrechts , W. De Roock, H. Prenen et al., “The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 15, supplement, 2009, abstract no. 4020. View at Google Scholar
  55. N. Irahara, Y. Baba, K. Nosho et al., “NRAS mutations are rare in colorectal cancer,” Diagnostic Molecular Pathology, vol. 19, no. 3, pp. 157–163, 2010. View at Publisher · View at Google Scholar · View at PubMed
  56. H. Davies, G. R. Bignell, C. Cox et al., “Mutations of the BRAF gene in human cancer,” Nature, vol. 417, no. 6892, pp. 949–954, 2002. View at Publisher · View at Google Scholar · View at PubMed
  57. J. Tol, I. D. Nagtegaal, and C. J. A. Punt, “BRAF mutation in metastatic colorectal cancer,” The New England Journal of Medicine, vol. 361, no. 1, pp. 98–99, 2009. View at Publisher · View at Google Scholar · View at PubMed
  58. S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli, “Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer,” Journal of the National Cancer Institute, vol. 101, no. 19, pp. 1308–1324, 2009. View at Publisher · View at Google Scholar · View at PubMed
  59. F. Di Nicolantonio, M. Martini, F. Molinari et al., “Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 35, pp. 5705–5712, 2008. View at Publisher · View at Google Scholar · View at PubMed
  60. P. Laurent-Puig, A. Cayre, G. Manceau et al., “Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 5924–5930, 2009. View at Publisher · View at Google Scholar · View at PubMed
  61. F. Loupakis, A. Ruzzo, C. Cremolini et al., “KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer,” British Journal of Cancer, vol. 101, no. 4, pp. 715–721, 2009. View at Publisher · View at Google Scholar · View at PubMed
  62. S. D. Richman, M. T. Seymour, P. Chambers et al., “KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 5931–5937, 2009. View at Publisher · View at Google Scholar · View at PubMed
  63. K. Cichowski and P. A. Jänne, “Drug discovery: inhibitors that activate,” Nature, vol. 464, no. 7287, pp. 358–359, 2010. View at Publisher · View at Google Scholar · View at PubMed
  64. P. I. Poulikakos, C. Zhang, G. Bollag, K. M. Shokat, and N. Rosen, “RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF,” Nature, vol. 464, no. 7287, pp. 427–430, 2010. View at Publisher · View at Google Scholar · View at PubMed
  65. G. Hatzivassiliou, K. Song, I. Yen et al., “RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth,” Nature, vol. 464, no. 7287, pp. 431–435, 2010. View at Publisher · View at Google Scholar · View at PubMed
  66. S. J. Heidorn, C. Milagre, S. Whittaker et al., “Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF,” Cell, vol. 140, no. 2, pp. 209–221, 2010. View at Publisher · View at Google Scholar · View at PubMed
  67. A. Duffy and S. Kummar, “Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors,” Targeted Oncology, vol. 4, no. 4, pp. 267–273, 2009. View at Publisher · View at Google Scholar · View at PubMed
  68. S. Daouti, B. Higgins, K. Kolinsky et al., “Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models,” Molecular Cancer Therapeutics, vol. 9, no. 1, pp. 134–144, 2010. View at Publisher · View at Google Scholar · View at PubMed
  69. J. Y. Yoon, K. H. Koo, and K. Y. Choi, “MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy,” Cancer Research, vol. 71, no. 2, pp. 445–453, 2011. View at Google Scholar
  70. C. Montagut and J. Settleman, “Targeting the RAF-MEK-ERK pathway in cancer therapy,” Cancer Letters, vol. 283, no. 2, pp. 125–134, 2009. View at Publisher · View at Google Scholar · View at PubMed
  71. D. B. Solit, L. A. Garraway, C. A. Pratilas et al., “BRAF mutation predicts sensitivity to MEK inhibition,” Nature, vol. 439, no. 7074, pp. 358–362, 2006. View at Publisher · View at Google Scholar · View at PubMed
  72. R. B. Corcoran, D. Dias-Santagata, K. Bergethon, A. J. Iafrate, J. Settleman, and J. A. Engelman, “BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation,” Science Signaling, vol. 3, no. 149, article ra84, 2010. View at Publisher · View at Google Scholar · View at PubMed
  73. A. Di Cristofano and P. P. Pandolfi, “The multiple roles of PTEN in tumor suppression,” Cell, vol. 100, no. 4, pp. 387–390, 2000. View at Google Scholar
  74. H. K. Roy, B. F. Olusola, D. L. Clemens et al., “AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis,” Carcinogenesis, vol. 23, no. 1, pp. 201–205, 2002. View at Google Scholar
  75. M. Jhawer, S. Goel, A. J. Wilson et al., “PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab,” Cancer Research, vol. 68, no. 6, pp. 1953–1961, 2008. View at Publisher · View at Google Scholar · View at PubMed
  76. Y. Samuels, Z. Wang, A. Bardelli et al., “High frequency of mutations of the PIK3CA gene in human cancers,” Science, vol. 304, no. 5670, p. 554, 2004. View at Publisher · View at Google Scholar · View at PubMed
  77. A. Sood, D. McClain, R. Seetharam et al., “Beyond KRAS: the quest for novel genetic markers predictive for response to anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer (mCRC),” Journal of Clinical Oncology, vol. 28, no. 15, supplement, 2010, ASCO Annual Meeting, abstract no. 3567. View at Google Scholar
  78. D. W. Parsons, T. L. Wang, Y. Samuels et al., “Colorectal cancer: mutations in a signalling pathway,” Nature, vol. 436, no. 7052, p. 792, 2005. View at Publisher · View at Google Scholar · View at PubMed
  79. C. A. Townsley, P. Major, L. L. Siu et al., “Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer,” British Journal of Cancer, vol. 94, no. 8, pp. 1136–1143, 2006. View at Publisher · View at Google Scholar · View at PubMed
  80. M. L. Rothenberg, B. LaFleur, D. E. Levy et al., “Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma,” Journal of Clinical Oncology, vol. 23, no. 36, pp. 9265–9274, 2005. View at Publisher · View at Google Scholar · View at PubMed
  81. J. A. Meyerhardt, A. X. Zhu, P. C. Enzinger et al., “Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer,” Journal of Clinical Oncology, vol. 24, no. 12, pp. 1892–1897, 2006. View at Publisher · View at Google Scholar · View at PubMed
  82. T. Kuo, C. D. Cho, J. Halsey et al., “Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5613–5619, 2005. View at Publisher · View at Google Scholar · View at PubMed
  83. M. G. Zampino, E. Magni, C. Massacesi et al., “First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer,” Cancer, vol. 110, no. 4, pp. 752–758, 2007. View at Publisher · View at Google Scholar · View at PubMed
  84. A. J. Weickhardt, T. J. Price, N. Pavlakis et al., “DUX study: a phase II study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, 2010, ASCO Annual Meeting Proceedings, abstract no. 3533. View at Google Scholar
  85. J. R. Tonra, D. S. Deevi, E. Corcoran et al., “Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy,” Clinical Cancer Research, vol. 12, no. 7, pp. 2197–2207, 2006. View at Publisher · View at Google Scholar · View at PubMed
  86. N. C. Tebbutt, D. Kotasek, H. A. Burris et al., “Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC),” in Proceedings of the ASCO Annual Meeting, 2010, abstract no. 3538.
  87. S. Kopetz, J. Desai, E. Chan et al., “PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, 2010, abstract no. 3534. View at Google Scholar
  88. C. Eng, J. Tabernero, E. Nowara et al., “Panitumumab (pmab) plus AMG 102 in patients (pts) with wild-type KRAS metastatic colorectal cancer (mCRC): updated safety results,” Journal of Clinical Oncology, vol. 28, supplement, 2010, ASCO Annual Meeting, abstract no. e14083. View at Google Scholar
  89. M. Di Salvatore, A. Inno, A. Orlandi et al., “KRAS and BRAF mutational status and PTEN, cMET, and IGF1R expression as predictive markers of response to cetuximab plus chemotherapy in metastatic colorectal cancer (mCRC),” Journal of Clinical Oncology, vol. 28, supplement, 2010, ASCO Annual Meeting, abstract no. e14065. View at Google Scholar
  90. S. R. Alberts, D. J. Sargent, T. C. Smyrk et al., “Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG Intergroup Phase III Trial N0147,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, 2010, ASCO Annual Meeting, abstract no. CRA3507. View at Google Scholar
  91. R. M. Goldberg, D. J. Sargent, and S. N. Thibodeau, “Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, 2010, ASCO Annual Meeting, abstract no. 3508. View at Google Scholar
  92. J. Giralt, M. de las Heras, L. Cerezo et al., “The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis,” Radiotherapy and Oncology, vol. 74, no. 2, pp. 101–108, 2005. View at Publisher · View at Google Scholar
  93. J. S. Kim, J. M. Kim, S. Li et al., “Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 66, no. 1, pp. 195–200, 2006. View at Publisher · View at Google Scholar · View at PubMed
  94. K. Y. Chung, B. Minsky, D. Schrag et al., “Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer,” Journal of Clinical Oncology, vol. 24, no. 18, supplement, 2006, abstract no. 3560. View at Google Scholar
  95. R. D. Hofheinz, K. Horisberger, C. Woernle et al., “Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer,” International Journal of Radiation Oncology Biology Physics, vol. 66, no. 5, pp. 1384–1390, 2006. View at Publisher · View at Google Scholar · View at PubMed
  96. J. P. Machiels, C. Sempoux, P. Scalliet et al., “Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer,” Annals of Oncology, vol. 18, no. 4, pp. 738–744, 2007. View at Publisher · View at Google Scholar · View at PubMed
  97. C. Rödel, D. Arnold, M. Hipp et al., “Phase I-II Trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer,” International Journal of Radiation Oncology Biology Physics, vol. 70, no. 4, pp. 1081–1086, 2008. View at Publisher · View at Google Scholar · View at PubMed
  98. K. Horisberger, A. Treschl, S. Mai et al., “Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial,” International Journal of Radiation Oncology Biology Physics, vol. 74, no. 5, pp. 1487–1493, 2009. View at Publisher · View at Google Scholar · View at PubMed
  99. F. Bertolini, S. Chiara, C. Bengala et al., “Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer,” International Journal of Radiation Oncology Biology Physics, vol. 73, no. 2, pp. 466–472, 2009. View at Publisher · View at Google Scholar · View at PubMed
  100. V. Velenik, J. Ocvirk, I. Oblak, and F. Anderluh, “A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer,” European Journal of Surgical Oncology, vol. 36, no. 3, pp. 244–250, 2010. View at Publisher · View at Google Scholar · View at PubMed
  101. C. Bengala, S. Bettelli, F. Bertolini et al., “Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer,” Annals of Oncology, vol. 20, no. 3, pp. 469–474, 2009. View at Publisher · View at Google Scholar · View at PubMed
  102. A. Debucquoy, K. Haustermans, A. Daemen et al., “Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer,” Journal of Clinical Oncology, vol. 27, no. 17, pp. 2751–2757, 2009. View at Publisher · View at Google Scholar · View at PubMed
  103. K. J. Williams, B. A. Telfer, I. J. Stratford, and S. R. Wedge, “ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model,” British Journal of Cancer, vol. 86, no. 7, pp. 1157–1161, 2002. View at Google Scholar
  104. V. Valentini, A. De Paoli, M. A. Gambacorta et al., “Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II trial (1839IL/0092),” International Journal of Radiation Oncology Biology Physics, vol. 72, no. 3, pp. 644–649, 2008. View at Publisher · View at Google Scholar · View at PubMed
  105. L. S. Blaszkowsky, T. S. Hong, A. X. Zhu et al., “A phase I/II study of bevacizumab, erlotinib, and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer,” Journal of Clinical Oncology, vol. 27, no. 15, supplement, p. 194S, 2009, abstract no. 4106. View at Google Scholar